Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals — Investor Presentation (January 2023)

41 slides from Theseus Pharmaceuticals's investor presentation, Jan 5, 2023

  1. Slide 1: Theseus Pharmaceuticals: A new generation of medicines to address cancer resistance

    Theseus Pharmaceuticals A new generation of medicines to address cancer resistance January 2023 | THRX

  2. Slide 2: Legal notice and forward-looking statements

    Legal notice and forward - looking statements 2 ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward - looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of

  3. Slide 3: Theseus is on a mission to outsmart cancer resistance

    Theseus is on a mission to outsmart cancer resistance.

  4. Slide 4: Theseus' mission to outsmart cancer resistance

    ©2023 Theseus Pharmaceuticals. Theseus is developing next - generation, single molecule pan - variant TKI candidates for treatment - resistant cancer Led by world - class R&D team with deep experience developing and commercializing novel targeted therapies in validated areas of unmet medical need Di

  5. Slide 5: Executing on a novel pipeline of targeted therapies

    Second program: THE - 349 (EGFR - mutant NSCLC) Lead program: THE - 630 (GIST) • KIT - driven GIST is a clonally heterogeneous disease which requires a pan - variant inhibitor to meaningfully improve patient outcomes • Enrolling patients in Phase 1 portion of Phase 1/2 study; expect preliminary dose

  6. Slide 6: World-class management team leveraging heritage of success

    Bill Shakespeare, Ph.D. Co - founder, President of R&D Former VP Drug Discovery, ARIAD World - class management team leveraging heritage of success Vic Rivera, Ph.D. Co - founder, CSO Former VP Preclinical & Translational Research, ARIAD David Kerstein, M.D. CMO Former CMO, Anchiano Former Sr. Med D

  7. Slide 7: Extensive experience and track record in TKI discovery, development, and commercialization

    Extensive experience and track record in TKI discovery, development, and commercialization 7 ©2023 Theseus Pharmaceuticals. Validated methodology & approach at ARIAD that produced three approved TKIs World - class team Leveraging prior achievements in the discovery, development and commercialization

  8. Slide 8: The problem

    The p roblem 8 ©2023 Theseus Pharmaceuticals. Tumor On - target resistance mutations emerge in response to targeted therapies , limiting the efficacy of such therapies Clonal heterogeneity develops over time, leading to disease complexity and tumor progression

  9. Slide 9: Our solution

    Our solution 9 ©2023 Theseus Pharmaceuticals. Tumor Theseus’ next - generation, pan - variant TKIs are designed to simultaneously inhibit all major cancer - causing and resistance mutations , which has the potential to yield prolonged clinical benefit in early and late lines of treatment

  10. Slide 10: Theseus' approach: TKI candidates developed iteratively to optimize pan-variant activity

    Theseus’ approach: TKI candidates are developed iteratively to optimize pan - variant activity 10 ©2023 Theseus Pharmaceuticals. Structure - Guided Design In silico : Uses 3D structures of the target TK to design a TKI with multiple molecular touch points to maintain binding in the presence of any v

  11. Slide 11: Growing pipeline of targeted cancer therapies

    Growing pipeline of targeted cancer therapies 11 ©2023 Theseus Pharmaceuticals. Note: We hold a worldwide exclusive license to THE - 630 in our therapeutic area of focus through the ARIAD License Agreement, as define d and described in our filings with the Securities and Exchange Commission. PROGRAM

  12. Slide 12: THE-630: Pan-variant KIT Inhibitor Candidate

    THE - 630: Pan - variant KIT Inhibitor Candidate

  13. Slide 13: Gastrointestinal stromal tumors (GIST) overview

    Gastrointestinal stromal tumors (GIST) overview 13 ©2023 Theseus Pharmaceuticals. GIST is the most common sarcoma of the GI tract with ~4,000 - 6,000 new cases in the U.S. each year • ~80% of GIST patients present with an activating mutation in KIT • KIT remains a primary driver in these patients th

  14. Slide 14: All current treatment options for GIST patients have deficiencies

    All current treatment options for GIST patients have deficiencies 14 ©2023 Theseus Pharmaceuticals. Response rates are measured in the single digits after imatinib failure, and progression occurs between four and seven months after receiving treatment Sources: Clarivate , DRG, Gleevec ® (imatinib) U

  15. Slide 15: PRA is designed to predict the observed deficiencies in GIST TKIs

    PRA is designed to predict the observed deficiencies in GIST TKIs ©2023 Theseus Pharmaceuticals. Cav = average serum concentration, and is calculated as the Area Under the Curve, or AUC, over a 24 - hour period and divided by 2 4. nM = nanomolar. (1) Width of clusters represents prevalence of specif

  16. Slide 16: Clinical data suggest a pan-variant inhibitor is critical in 2L GIST

    Clinical data suggest a pan - variant inhibitor is critical for effective treatment in patients with 2L GIST ©2023 Theseus Pharmaceuticals. Sources: Theseus analysis of Wellcome Sanger Institute compilation of major GIST publications, including CCR 2007;13(18 Pt 1):5398 - 405, CCR 2006;12(6):1743 -

  17. Slide 17: INTRIGUE subgroup analysis highlights power of the PRA

    INTRIGUE subgroup analysis highlights power of the PRA and potential for THE - 630 in 2L GIST ©2023 Theseus Pharmaceuticals. Source: Deciphera Pharmaceuticals INTRIGUE ctDNA Analysis Conference Call Presentation, Jan. 3, 2023. (1) In PRA plot, ripretinib resistance mutation in exon 17/18 shown above

  18. Slide 18: THE-630 could be the only therapy covering all major mutation classes

    THE - 630 could be the only therapy with coverage of all major classes of activating and resistance mutations ©2023 Theseus Pharmaceuticals. Based on data from our PRA. PR/CR means partial/complete response; SD means stable disease; PD means progressive disease. (1) Assumes target Cav of 100 nM. 18

  19. Slide 19: THE-630 has the profile of a pan-KIT inhibitor for GIST in vivo

    THE - 630 has the profile of a pan - KIT inhibitor for GIST in vivo 19 ©2023 Theseus Pharmaceuticals. Ba/F3 tumor model shown. QD = once daily dosing. BID = twice daily dosing. • Ripretinib: Strong anti - tumor activity against Exon 17 D820A mutation but not Exon 13 V654A mutation • THE - 630: Stron

  20. Slide 20: Designed to avoid key off-target effects, notably FLT3 inhibition

    Designed to avoid key off - target effects, notably FLT3 inhibition • Kinome selectivity in vitro comparable to ripretinib , which is clinically well - tolerated • S - scores (50) for THE - 630 and ripretinib ~0.15 (46/300 and 44/300 kinases inhibited by >50% at 100 nM respectively) THE - 630 was we

  21. Slide 21: Phase 1/2 dose escalation and expansion trial in advanced GIST

    Phase 1/2 dose escalation and expansion trial in patients with advanced GIST (NCT05160168) 21 ©2023 Theseus Pharmaceuticals. • Currently enrolling the dose - escalation portion of the Phase 1/2 clinical trial for THE - 630 in previously - treated GIST patients Enrollment Criteria • Patients with adv

  22. Slide 22: THE-630 Phase 1 dose escalation

    THE - 630 Phase 1 dose escalation 22 ©2023 Theseus Pharmaceuticals. • 3+3 dose escalation design, once - daily dosing • All seven sites open and enrolling − Dosing cohort 5 as of the end of 2022 − Median 4 prior therapies • Expect 100 nM target Cav to be achieved at ~7 - 8 dose cohorts, with backfil

  23. Slide 23: Registration strategy for THE-630: rapidly advance to 2L

    Registration strategy for THE - 630: rapidly advance to 2L 23 ©2023 Theseus Pharmaceuticals. Targeting rapid advancement to 2L development, with plans to commence a 2L registrational study shortly after beginning our 5L registrational study Ongoing dose escalation Planned Phase 2 dose expansion Plan

  24. Slide 24: THE-349: Fourth-Generation EGFR Inhibitor Candidate

    THE - 349: Fourth - Generation EGFR Inhibitor Candidate

  25. Slide 25: EGFRm NSCLC overview

    EGFRm NSCLC overview 25 ©2023 Theseus Pharmaceuticals. There is no approved TKI to address all combinations of major EGFR activating and resistance mutations • EGFR mutations are a key driver of NSCLC, with approximately 18,000 first - line EGFRm NSCLC patients in the United States with mutations in

  26. Slide 26: Treatment paradigm for EGFRm NSCLC

    Treatment paradigm for EGFRm NSCLC 26 ©2023 Theseus Pharmaceuticals. Exon 9 (10%) Exon 11 (70%) Activating Mutations Resistance Mutations Exon 13 - 14 (~40 %) ATP Binding Pocket Exon 17 - 18 (~40 %) Activation Loo p Exon 19 deletion ( D ) or L858R ( L ) activating mutation EGFR mutation T790M resist

  27. Slide 27: THE-349 potently inhibits single-, double-, and triple-mutants

    Preclinical data has demonstrated THE - 349 potently inhibits single - , double - , and triple - mutants, including T790M and C797X 27 ©2023 Theseus Pharmaceuticals. Mutational Coverage L858R or Exon 19 del L858R or Exon 19 del + T790M L858R or Exon 19 del + C797X L858R or Exon 19 del + T790M + C797

  28. Slide 28: THE-349 exhibits potent and selective EGFR mutant activity

    THE - 349 exhibits potent and selective EGFR mutant activity with significant kinome selectivity in vitro 28 ©2023 Theseus Pharmaceuticals. THE - 349 demonstrates low nanomolar IC50 values against single - , double - and triple - mutant EGFR variants with wild - type selectivity which exceeds that o

  29. Slide 29: THE-349 has robust tumor regression activity in mouse models

    THE - 349 has robust tumor regression activity in mouse models expressing EGFR single - , double - and triple - mutant variants at well - tolerated doses 29 ©2023 Theseus Pharmaceuticals. Note: TR = Tumor Regression. TGI = Tumor Growth Inhibition. Ba/F3 tumor models shown. Dosing is once daily. Data

  30. Slide 30: THE-349 is active in CNS and has favorable drug-like properties

    THE - 349 is active in CNS and has displayed favorable drug - like properties in mouse models 30 ©2023 Theseus Pharmaceuticals. Note: Data from the 2022 EORTC - NCI - AACR ( ENA ) Symposium. Poster # 236 THE - 349 demonstrates significant anti - tumor activity in H1975 LTC and PC9 (D) intracranial m

  31. Slide 31: THE-349 induced deep, durable regressions in osimertinib-resistant PDX model

    THE - 349 induced deep, durable regressions in clonally heterogeneous osimertinib - resistant PDX model ©2023 Theseus Pharmaceuticals. Confidential Information. Model developed from patient with NSCLC after failure of >5 lines of therapy (including erlotinib and osimertinib) • Model reflects clonal

  32. Slide 32: Clinical development plan for THE-349

    Clinical development plan for THE - 349 32 ©2023 Theseus Pharmaceuticals. Theseus plans to pursue an initial registration as monotherapy in patients with on - target resistance, as well as rapidly expand into evaluation of combinations and, if clinical data support, target the broader 2L market, whi

  33. Slide 33: BCR-ABL Program

    @) THESEUS BCR-ABL Program

  34. Slide 34: Approved BCR-ABL inhibitors have limitations balancing efficacy and safety

    Approved BCR - ABL inhibitors have limitations because they do not optimally balance efficacy and safety 34 ©2023 Theseus Pharmaceuticals. Generation Safety/tolerability (1) Efficacy/pan - ness (2) CML Indication Adult Ph+ ALL Indication Theseus BCR - ABL inhibitor TPP 5G ≥2L ( target ) 1L ( target

  35. Slide 35: Key features of CML

    Key features of CML 35 ©2023 Theseus Pharmaceuticals. • Disease remains BCR - ABL driven through multiple lines of therapy, and patients commonly will relapse with a BCR - ABL resistance mutation • Multiple therapies have been approved; however, approximately 30% to 40% of patients started on any TK

  36. Slide 36: Key features of adult Ph+ ALL

    Key features of adult Ph+ ALL 36 ©2023 Theseus Pharmaceuticals. • Newly diagnosed adults have historically received chemotherapy followed by allogeneic hematopoietic stem - cell transplant (HSCT), and more recently the addition of BCR - ABL TKIs have improved outcomes in 1L treatment, despite their

  37. Slide 37: Target product profile for Theseus' pan-variant BCR-ABL TKI

    Target product profile for Theseus’ pan - variant BCR - ABL TKI 37 ©2023 Theseus Pharmaceuticals. Compound Company Generation 2021 FY Sales (USD) Imatinib (Gleevec ® ) Novartis 1G $1.0bn Dasatinib ( Sprycel ®) Bristol Myers Squibb 2G $2.1bn Nilotinib ( Tasigna ®) Novartis 2G $2.0bn Bosutinib ( Bosul

  38. Slide 38: In vitro characterization showed pan-BCR-ABL activity with increased selectivity versus ponatinib

    In vitro characterization demonstrated pan - BCR - ABL activity with increased selectivity versus ponatinib 38 ©2023 Theseus Pharmaceuticals. On - target BCR - ABL potency (BaF3 IC50 nM) Off - target potency (BaF3 IC50 nM) Endothelial cell tox (IC 25 nM) Kinome selectivity Cmpd WT T315I E255V F359V

  39. Slide 39: Theseus molecule showed similar tumor regression and superior tolerability to ponatinib

    Theseus molecule showed similar tumor regression activity and superior tolerability to ponatinib in vivo 39 ©2023 Theseus Pharmaceuticals. Activity against most recalcitrant mutant (E255V) Compound 1 induced strong tumor regressions against the most recalcitrant mutant and demonstrated improved tole

  40. Slide 40: Strong pipeline developed by world-class team

    Strong pipeline developed by world - class team 40 ©2023 Theseus Pharmaceuticals. Second program: THE - 349 (EGFR - mutant NSCLC) Lead program: THE - 630 (GIST) • KIT - driven GIST is a clonally heterogeneous disease which requires a pan - variant inhibitor to meaningfully improve patient outcomes •

  41. Slide 41: © THESEUS

    © THESEUS

Theseus Pharmaceuticals — Investor Presentation (January 2023) on 6ix